Vivek Subbiah: Honored to co-author with brilliant “Guru” of bladder cancer Guru Sonpavde.

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post by Guru Sonpavde, Professor of Medicine at the University of Central Florida, on LinkedIn, adding:

“Hot off the press. Exciting weekend read alert!
Unlocking Precision Oncology with FGFR Inhibition in Urothelial Carcinoma. Check out our latest editorial in ESMO – European Society for Medical Oncology journal Annals of Oncology by the brilliant “Guru” of bladder cancer Guru Sonpavde, MD.
Honored to co-author and contribute insights on Precision Oncology. Let’s pave the way for targeted therapies!”

Quoting Guru Sonpavde’s post:

“Unlocking precision oncology with FGFR Inhibition in urothelial carcinoma, bladder cancer – how do we further develop FGFR inhibitors in this disease? Might all of the following play a role: 1) understanding resistance, 2) optimal combinations (?PD1 inh, EV, PI3K/AKT inh), 3) optimal trial paradigms (?tumor agnostic basket trials), 4) earlier disease settings, 5) optimize delivery for better therapeutic index (intravesical)- honored to write this editorial in Annals of Oncology with esteemed coauthor Vivek Subbiah, MD Sarah Cannon Research Institute regarding paper by Andrea Necchi on pemigatinib for this disease”

For the article click here.
Sources: Vivek Subbiah/LinkedIn and Guru Sonpavde/LinkedIn